NASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis $0.80 -0.05 (-5.35%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.25%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aprea Therapeutics Stock (NASDAQ:APRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aprea Therapeutics alerts:Sign Up Key Stats Today's Range$0.77▼$0.9050-Day Range$0.67▼$1.0052-Week Range$0.55▼$2.22Volume146,727 shsAverage Volume204,129 shsMarket Capitalization$9.90 millionP/E RatioN/ADividend YieldN/APrice Target$4.07Consensus RatingHold Company Overview Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations. Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS. In addition to its lead program, Aprea maintains a pipeline of early‐stage candidates and explores combination regimens intended to enhance response rates and overcome resistance mechanisms associated with TP53 dysfunction. Aprea conducts global clinical development activities, collaborating with academic centers and biopharmaceutical partners in North America and Europe. These partnerships support Aprea’s efforts to accelerate trial enrollment, broaden access to investigational therapies and facilitate regulatory interactions across multiple jurisdictions. Founded in 2013 and headquartered in San Francisco, California, Aprea is led by a management team with extensive experience in oncology drug development. The company’s scientific leadership combines expertise in molecular biology, translational research and clinical operations to advance its precision oncology approach for patients with high‐unmet‐need cancers.AI Generated. May Contain Errors. Read More Aprea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreAPRE MarketRank™: Aprea Therapeutics scored higher than 84% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAprea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAprea Therapeutics has a consensus price target of $4.07, representing about 408.3% upside from its current price of $0.80.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($0.83) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.96% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 0.39, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 6.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.73 News SentimentAprea Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aprea Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.63% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APRE Stock News HeadlinesAprea Therapeutics (NASDAQ:APRE) Price Target Lowered to $6.00 at WedbushMay 15, 2026 | americanbankingnews.comAprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 TrialMay 13, 2026 | quiverquant.comQNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 13, 2026 | globenewswire.comAprea Therapeutics (APRE) Expected to Announce Earnings on WednesdayMay 11, 2026 | americanbankingnews.comOppenheimer initiates coverage of Aprea Therapeutics (APRE) with outperform recommendationMay 9, 2026 | msn.comCatalYm Appoints Christian S. Schade as Chairman of the Board of DirectorsApril 29, 2026 | finance.yahoo.comAprea Therapeutics Announces Acceptance of Abstract for Phase 1 Study of WEE1 Inhibitor APR-1051 at ASCO 2026April 21, 2026 | quiverquant.comQSee More Headlines APRE Stock Analysis - Frequently Asked Questions How have APRE shares performed this year? Aprea Therapeutics' stock was trading at $0.8530 at the beginning of the year. Since then, APRE stock has decreased by 6.2% and is now trading at $0.80. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company earned $0.28 million during the quarter, compared to analysts' expectations of $0 million. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative trailing twelve-month return on equity of 61.03%. When did Aprea Therapeutics' stock split? Aprea Therapeutics's stock reverse split on Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $85 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,666,667 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO. Who are Aprea Therapeutics' major shareholders? Aprea Therapeutics' top institutional shareholders include AIGH Capital Management LLC (8.47%). Insiders that own company stock include Oren Gilad, Marc Duey, Bernd R Seizinger and John P Hamill. View institutional ownership trends. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings5/13/2026Today5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 APRE's financial health is in the Green zone, according to TradeSmith. APRE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APRE CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Aprea Therapeutics$4.07 High Price Target$6.00 Low Price Target$1.20 Potential Upside/Downside+408.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.60 million Net Margins-4,405.59% Pretax Margin-9,719.51% Return on Equity-61.03% Return on Assets-50.24% Debt Debt-to-Equity RatioN/A Current Ratio8.92 Quick Ratio8.92 Sales & Book Value Annual Sales$290 thousand Price / Sales34.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.36 per share Price / Book0.24Miscellaneous Outstanding Shares12,380,000Free Float10,695,000Market Cap$9.90 million OptionableNo Data Beta1.48 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:APRE) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
